Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,044 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.
Matsuda K, Migueles SA, Huang J, Bolkhovitinov L, Stuccio S, Griesman T, Pullano AA, Kang BH, Ishida E, Zimmerman M, Kashyap N, Martins KM, Stadlbauer D, Pederson J, Patamawenu A, Wright N, Shofner T, Evans S, Liang CJ, Candia J, Biancotto A, Fantoni G, Poole A, Smith J, Alexander J, Gurwith M, Krammer F, Connors M. Matsuda K, et al. Among authors: alexander j. J Clin Invest. 2021 Mar 1;131(5):e140794. doi: 10.1172/JCI140794. J Clin Invest. 2021. PMID: 33529172 Free PMC article. Clinical Trial.
Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study.
Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, Webby R, Wright PF. Gurwith M, et al. Among authors: alexander j. Lancet Infect Dis. 2013 Mar;13(3):238-50. doi: 10.1016/S1473-3099(12)70345-6. Epub 2013 Jan 29. Lancet Infect Dis. 2013. PMID: 23369412 Free PMC article. Clinical Trial.
Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.
Khurana S, Coyle EM, Manischewitz J, King LR, Ishioka G, Alexander J, Smith J, Gurwith M, Golding H. Khurana S, et al. Among authors: alexander j. PLoS One. 2015 Jan 28;10(1):e0115476. doi: 10.1371/journal.pone.0115476. eCollection 2015. PLoS One. 2015. PMID: 25629161 Free PMC article.
Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
Malherbe DC, Mendy J, Vang L, Barnette PT, Reed J, Lakhashe SK, Owuor J, Gach JS, Legasse AW, Axthelm MK, LaBranche CC, Montefiori D, Forthal DN, Park B, Wilson JM, McLinden JH, Xiang J, Stapleton JT, Sacha JB, Haynes BF, Liao HX, Ruprecht RM, Smith J, Gurwith M, Haigwood NL, Alexander J. Malherbe DC, et al. Among authors: alexander j. J Virol. 2018 Jan 2;92(2):e01092-17. doi: 10.1128/JVI.01092-17. Print 2018 Jan 15. J Virol. 2018. PMID: 29093095 Free PMC article.
Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge.
Espinosa D, Mendy J, Manayani D, Vang L, Wang C, Richard T, Guenther B, Aruri J, Avanzini J, Garduno F, Farness P, Gurwith M, Smith J, Harris E, Alexander J. Espinosa D, et al. Among authors: alexander j. EBioMedicine. 2018 Jan;27:61-70. doi: 10.1016/j.ebiom.2017.12.010. Epub 2017 Dec 12. EBioMedicine. 2018. PMID: 29269041 Free PMC article.
Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine.
Matsuda K, Huang J, Zhou T, Sheng Z, Kang BH, Ishida E, Griesman T, Stuccio S, Bolkhovitinov L, Wohlbold TJ, Chromikova V, Cagigi A, Leung K, Andrews S, Cheung CSF, Pullano AA, Plyler J, Soto C, Zhang B, Yang Y, Joyce MG, Tsybovsky Y, Wheatley A, Narpala SR, Guo Y, Darko S, Bailer RT, Poole A, Liang CJ, Smith J, Alexander J, Gurwith M, Migueles SA, Koup RA, Golding H, Khurana S, McDermott AB, Shapiro L, Krammer F, Kwong PD, Connors M. Matsuda K, et al. Among authors: alexander j. Sci Immunol. 2019 Apr 19;4(34):eaau2710. doi: 10.1126/sciimmunol.aau2710. Sci Immunol. 2019. PMID: 31004012 Clinical Trial.
Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.
Alexander J, Mendy J, Vang L, Avanzini JB, Garduno F, Manayani DJ, Ishioka G, Farness P, Ping LH, Swanstrom R, Parks R, Liao HX, Haynes BF, Montefiori DC, LaBranche C, Smith J, Gurwith M, Mayall T. Alexander J, et al. PLoS One. 2013 Dec 3;8(12):e82380. doi: 10.1371/journal.pone.0082380. eCollection 2013. PLoS One. 2013. PMID: 24312658 Free PMC article.
Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge.
Malherbe DC, Vang L, Mendy J, Barnette PT, Spencer DA, Reed J, Kareko BW, Sather DN, Pandey S, Wibmer CK, Robins H, Fuller DH, Park B, Lakhashe SK, Wilson JM, Axthelm MK, Ruprecht RM, Moore PL, Sacha JB, Hessell AJ, Alexander J, Haigwood NL. Malherbe DC, et al. Among authors: alexander j. Front Immunol. 2021 Feb 15;11:626464. doi: 10.3389/fimmu.2020.626464. eCollection 2020. Front Immunol. 2021. PMID: 33658998 Free PMC article.
Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus.
Vang L, Morello CS, Mendy J, Thompson D, Manayani D, Guenther B, Julander J, Sanford D, Jain A, Patel A, Shabram P, Smith J, Alexander J. Vang L, et al. Among authors: alexander j. PLoS Negl Trop Dis. 2021 Mar 12;15(3):e0009195. doi: 10.1371/journal.pntd.0009195. eCollection 2021 Mar. PLoS Negl Trop Dis. 2021. PMID: 33711018 Free PMC article.
6,044 results